

Spark NIR™ 685 anti-human CD62L

Catalog # / Size: 2124310 / 100 tests
2124305 / 25 tests

Clone: DREG-56

Isotype: Mouse IgG1, κ

Immunogen: Concentrated supernatant from PMA-activated human peripheral blood leukocytes


Reactivity: Human, Other

Preparation: The antibody was purified by affinity chromatography and conjugated with Spark NIR™ 685 under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

Workshop Number: V S056

Concentration: Lot-specific




Human peripheral blood lymphocytes were stained with CD62L (clone DREG-56) Spark NIR™ 685 (filled histogram) or mouse IgG1, κ Spark NIR™ 685 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µL per million cells in 100 µL staining volume or 5 µL per 100 µL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



* Spark NIR™ 685 has a maximum excitation of 665 nm and a maximum emission of 685 nm.

Application Notes: Additional reported applications (for the relevant formats) include: Western blotting^{2,3,9} and *in vitro* blocking of lymphocytes binding to high endothelial venules (HEV)². The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. Nos. 304853-304858).

**Application
References:**

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
 2. Kishimoto TK, et al. 1990. *Proc. Natl. Acad. Sci. USA* 87:2244. (WB, Block)
 3. Jutila M, et al. 2002. *J. Immunol.* 169:1768. (WB)
 4. Tamassia N, et al. 2008. *J. Immunol.* 181:6563. (FC) [PubMed](#)
 5. Kmiecik M, et al. 2009. *J. Transl. Med.* 7:89. (FC) [PubMed](#)
 6. Thakral D, et al. 2008. *J. Immunol.* 180:7431. (FC) [PubMed](#)
 7. Charles N, et al. 2010. *Nat. Med.* 16:701. (FC) [PubMed](#)
 8. Yoshino N, et al. 2000. *Exp. Anim. (Tokyo)* 49:97. (FC)
 9. Koenig JM, et al. 1996. *Pediatr. Res.* 39:616. (WB)
 10. Shi C, et al. 2011. *J. Immunol.* 187:5293. (FC) [PubMed](#)
 11. Burges M, et al. 2013. *Clin Cancer Res.* 19:5675. [PubMed](#)
 12. Cash JL, et al. 2013. *EMBO Rep.* 14:999. (FC) [PubMed](#)
-

Description:

CD62L is a 74-95 kD single chain type I glycoprotein referred to as L-selectin or LECAM-1. It is expressed on most peripheral blood B cells, subsets of T and NK cells, monocytes, granulocytes, and certain hematopoietic malignant cells. CD62L binds to carbohydrates present on certain glycoforms of CD34, glycam-1, and MAdCAM-1 and with a low affinity to anionic oligosaccharide sequences related to sialylated Lewis X (sLex, CD15s) through its C-type lectin domain. CD62L is important for the homing of naïve lymphocytes to high endothelial venules in peripheral lymph nodes and Peyer's patches. It also plays a role in leukocyte rolling on activated endothelial cells.

**Antigen
References:**

1. Kishimoto T, et al. 1990. *P. Natl. Acad. Sci. USA* 87:2244.
2. Kishimoto T, et al. 1991. *Blood* 78:805.